PURPOSE: The chick chorioallantoic membrane (CAM) assay can provide an alternative versatile, cost-effective, and ethically less controversial in vivo model for reliable screening of drugs. In the presented work, we demonstrate that CAM assay (in ovo and ex ovo) can be simply employed to delineate the effects of cisplatin (CDDP) and ellipticine (Elli) on neuroblastoma (Nbl) cells in terms of their growth and metastatic potential. METHODS: The Nbl UKF-NB-4 cell line was established from recurrent bone marrow metastases of high-risk Nbl (stage IV, MYCN amplification, 7q21 gain). Ex ovo and in ovo CAM assays were optimized to evaluate the antimetastatic activity of CDDP and Elli. Immunohistochemistry, qRT-PCR, and DNA isolation were performed. RESULTS: Ex ovo CAM assay was employed to study whether CDDP and Elli exhibit any inhibitory effects on growth of Nbl xenograft in ex ovo CAM assay. Under the optimal conditions, Elli and CDDP exhibited significant inhibition of the size of the primary tumor. To study the efficiency of CDDP and Elli to inhibit primary Nbl tumor growth, intravasation, and extravasation in the organs, we adapted the in ovo CAM assay protocol. In in ovo CAM assay, both studied compounds (CDDP and Elli) exhibited significant (p < 0.001) inhibitory activity against extravasation to all investigated organs including distal CAM. CONCLUSIONS: Taken together, CAM assay could be a helpful and highly efficient in vivo approach for high-throughput screening of libraries of compounds with expected anticancer activities.

Central European Institute of Technology Brno University of Technology Brno Czechia

Centro de Investigación Biomédica en Red de Cáncer Instituto de Salud Carlos 3 Madrid Spain

Instituto de Biomedicina y Biotecnología de Cantabria Universidad de Cantabria Santander Spain

Research Group for Molecular Biology and Nanomedicine Department of Chemistry and Biochemistry Mendel University in Brno Brno Czechia

Zobrazit více v PubMed

Melaiu O, Chierici M, Lucarini V, Jurman G, Conti LA, De Vito R, et al. . Cellular and Gene Signatures of Tumor-Infiltrating Dendritic Cells and Natural-Killer Cells Predict Prognosis of Neuroblastoma. Nat Commun (2020) 11(1):1–15. 10.1038/s41467-020-19781-y PubMed DOI PMC

Schor NF. Neuroblastoma as a Clinical Entity. In: Schor NF, editor. The Neurology of Neuroblastoma: Neuroblastoma as a Neurobiological Disease. Boston, MA, USA: Springer US; (2002). p. 25–51.

Ganeshan VR, Schor NF. Pharmacologic Management of High-Risk Neuroblastoma in Children. Paediatr Drugs (2011) 13(4):245–55. 10.2165/11591630-000000000-00000 PubMed DOI PMC

Trigg RM, Lee LC, Prokoph N, Jahangiri L, Reynolds CP, Burke GAA, et al. . The Targetable Kinase PIM1 Drives ALK Inhibitor Resistance in High-Risk Neuroblastoma Independent of MYCN Status. Nat Commun (2019) 10:1–13. 10.1038/s41467-019-13315-x PubMed DOI PMC

Jung J. Human Tumor Xenograft Models for Preclinical Assessment of Anticancer Drug Development. Toxicol Res (2014) 30(1):1–5. 10.5487/TR.2014.30.1.001 PubMed DOI PMC

Mapanao AK, Che PP, Sarogni P, Sminia P, Giovannetti E, Voliani V. Tumor Grafted – Chick Chorioallantoic Membrane as an Alternative Model for Biological Cancer Research and Conventional/Nanomaterial-Based Theranostics Evaluation. Expert Opin Drug Metab Toxicol (2021) 17(8):947–68.  10.1080/17425255.2021.1879047 PubMed DOI

Day C-P, Merlino G, Van Dyke T. Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges. Cell (2015) 163(1):39–53. 10.1016/j.cell.2015.08.068 PubMed DOI PMC

Mangir N, Raza A, Haycock JW, Chapple C, Macneil S. An Improved In Vivo Methodology to Visualise Tumour Induced Changes in Vasculature Using the Chick Chorionic Allantoic Membrane Assay. In Vivo (2018) 32(3):461–72. 10.21873/invivo.11262 PubMed DOI PMC

Gonzalez-Chavarria I, Cerro RP, Parra NP, Sandoval FA, Zuniga FA, Omazabal VA, et al. . Lectin-Like Oxidized LDL Receptor-1 Is an Enhancer of Tumor Angiogenesis in Human Prostate Cancer Cells. PloS One (2014) 9(8):1–11. 10.1371/journal.pone.0106219 PubMed DOI PMC

Jaworski S, Sawosz E, Grodzik M, Kutwin M, Wierzbicki M, Wlodyga K, et al. . Comparison of Tumour Morphology and Structure From U87 and U118 Glioma Cells Cultured on Chicken Embryo Chorioallantoic Membrane. Bull Vet Inst Pulawy (2013) 57(4):593–8. 10.2478/bvip-2013-0101 DOI

Kunz P, Schenker A, Sahr H, Lehner B, Fellenberg J. Optimization of the Chicken Chorioallantoic Membrane Assay as Reliable In Vivo Model for the Analysis of Osteosarcoma. PloS One (2019) 14(4):1–16. 10.1371/journal.pone.0215312 PubMed DOI PMC

Zhou X, Xu CJ, Wang JX, Dai T, Ye YP, Cui YM, et al. . Metastasis-Associated in Colon Cancer-1 Associates With Poor Prognosis and Promotes Cell Invasion and Angiogenesis in Human Cervical Cancer. Int J Gynecol Cancer (2015) 25(8):1353–63. 10.1097/IGC.0000000000000524 PubMed DOI PMC

Huang WT, Cen WL, He RQ, Xie Y, Zhang Y, Li P, et al. . Effect of miR-146a-5p on Tumor Growth in NSCLC Using Chick Chorioallantoic Membrane Assay and Bioinformatics Investigation. Mol Med Rep (2017) 16(6):8781–92. 10.3892/mmr.2017.7713 PubMed DOI PMC

Ppulo H, Nunes B, Sampaio C, Batista R, Pinto MT, Gaspar TB, et al. . Inhibitory Effects of Antagonists of Growth Hormone-Releasing Hormone (GHRH) in Thyroid Cancer. Horm Cancer (2017) 8(5-6):314–24. 10.1007/s12672-017-0307-4 PubMed DOI PMC

Rodrigo MAM, Michalkova H, Strmiska V, Casar B, Crespo P, de los Rios V, et al. . Metallothionein-3 Promotes Cisplatin Chemoresistance Remodelling in Neuroblastoma. Sci Rep (2021) 11(1):1–14. 10.1038/s41598-021-84185-x PubMed DOI PMC

Sys GML, Lapeire L, Stevens N, Favoreel H, Forsyth R, Bracke M, et al. . The In Ovo CAM-Assay as a Xenograft Model for Sarcoma. J Vis Exp (2013) (77):1–7. 10.3791/50522 PubMed DOI PMC

Mangir N, Dikici S, Claeyssens F, MacNeil S. Using Ex Ovo Chick Chorioallantoic Membrane (CAM) Assay To Evaluate the Biocompatibility and Angiogenic Response to Biomaterials. ACS Biomater Sci Eng (2019) 5(7):3190–200. 10.1021/acsbiomaterials.9b00172 PubMed DOI

Crespo P, Casar B. The Chick Embryo Chorioallantoic Membrane as an In Vivo Model to Study Metastasis. Bio-protoc (2016) 6(20):1–2. 10.21769/BioProtoc.1962 PubMed DOI

Herrero A, Pinto A, Colon-Bolea P, Casar B, Jones M, Agudo-Ibanez L, et al. . Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes. Cancer Cell (2015) 28(2):170–82. 10.1016/j.ccell.2015.07.001 PubMed DOI

Casar B, Rimann I, Kato H, Shattil SJ, Quigley JP, Deryugina EI. In Vivo Cleaved CDCP1 Promotes Early Tumor Dissemination via Complexing With Activated β1 Integrin and Induction of FAK/PI3K/Akt Motility Signaling. Oncogene (2014) 33(2):255–68. 10.1038/onc.2012.547 PubMed DOI PMC

Pinto MT, Ribeiro AS, Conde I, Carvalho R, Paredes J. The Chick Chorioallantoic Membrane Model: A New In Vivo Tool to Evaluate Breast Cancer Stem Cell Activity. Int J Mol Sci (2021) 22(1):1–14. 10.3390/ijms22010334 PubMed DOI PMC

Comsa S, Ceausu AR, Popescu R, Sarb S, Cimpean AM, Raica M. The MSC-MCF-7 Duet Playing Tumor Vasculogenesis and Angiogenesis Onto the Chick Embryo Chorioallantoic Membrane. In Vivo (2020) 34(6):3315–25. 10.21873/invivo.12170 PubMed DOI PMC

Ribatti D, Annese T, Tamma R. The Use of the Chick Embryo CAM Assay in the Study of Angiogenic Activity of Biomaterials. Microvasc Res (2020) 131:1–6. 10.1016/j.mvr.2020.104026 PubMed DOI

Naik M, Brahma P, Dixit M. A Cost-Effective and Efficient Chick Ex-Ovo CAM Assay Protocol to Assess Angiogenesis. Methods Protoc (2018) 1(2):1–19. 10.3390/mps1020019 PubMed DOI PMC

Ribatti D, Tamma R. The Chick Embryo Chorioallantoic Membrane as an In Vivo Experimental Model to Study Human Neuroblastoma. J Cell Physiol (2019) 234(1):152–7. 10.1002/jcp.26773 PubMed DOI

Swadi R, Mather G, Pizer BL, Losty PD, See V, Moss D. Optimising the Chick Chorioallantoic Membrane Xenograft Model of Neuroblastoma for Drug Delivery. BMC Cancer (2018) 18:1–11. 10.1186/s12885-017-3978-x PubMed DOI PMC

Ribatti D. The Chick Embryo Chorioallantoic Membrane as a Model for Tumor Biology. Exp Cell Res (2014) 328(2):314–24. 10.1016/j.yexcr.2014.06.010 PubMed DOI

Marshall KM, Kanczler JM, Oreffo ROC. Evolving Applications of the Egg: Chorioallantoic Membrane Assay and Ex Vivo Organotypic Culture of Materials for Bone Tissue Engineering. J Tissue Eng (2020) 11:1–25. 10.1177/2041731420942734 PubMed DOI PMC

Ribatti D. The Chick Embryo Chorioallantoic Membrane (CAM) Assay. Reprod Toxicol (2017) 70:97–101. 10.1016/j.reprotox.2016.11.004 PubMed DOI

Dünker N, Jendrossek V. Implementation of the Chick Chorioallantoic Membrane (CAM) Model in Radiation Biology and Experimental Radiation Oncology Research. Cancers (2019) 11(10):1499. 10.3390/cancers11101499 PubMed DOI PMC

Yogev O, Almeida GS, Barker KT, George SL, Kwok C, Campbell J, et al. . In Vivo Modeling of Chemoresistant Neuroblastoma Provides New Insights Into Chemorefractory Disease and Metastasis. Cancer Res (2019) 79(20):5382–93. 10.1158/0008-5472.CAN-18-2759 PubMed DOI

Amoroso L, Erminio G, Makin G, Pearson ADJ, Brock P, Valteau-Couanet D, et al. . Topotecan-Vincristine-Doxorubicin in Stage 4 High-Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC: A SIOPEN Study. Cancer Res Treat (2018) 50(1):148–55. 10.4143/crt.2016.511 PubMed DOI PMC

Johnsen JI, Dyberg C, Fransson S, Wickström M. Molecular Mechanisms and Therapeutic Targets in Neuroblastoma. Pharm Res (2018) 131:164–76. 10.1016/j.phrs.2018.02.023 PubMed DOI

Tsai JH, Yang J. Epithelial-Mesenchymal Plasticity in Carcinoma Metastasis. Genes Dev (2013) 27(20):2192–206. 10.1101/gad.225334.113 PubMed DOI PMC

Fennell DA, Summers Y, Cadranel J, Benepal T, Christoph DC, Lal R, et al. . Cisplatin in the Modern Era: The Backbone of First-Line Chemotherapy for non-Small Cell Lung Cancer. Cancer Treat Rev (2016) 44:42–50. 10.1016/j.ctrv.2016.01.003 PubMed DOI

Stiborova M, Sejbal J, Borek-Dohalska L, Aimova D, Poljakova J, Forsterova K, et al. . The Anticancer Drug Ellipticine Forms Covalent DNA Adducts, Mediated by Human Cytochromes P450, Through Metabolism to 13-Hydroxyellipticine and Ellipticine N2-Oxide. Cancer Res (2004) 64(22):8374–80. 10.1158/0008-5472.CAN-04-2202 PubMed DOI

Metallothionein-3 is a multifunctional driver that modulates the development of sorafenib-resistant phenotype in hepatocellular carcinoma cells

Chick chorioallantoic membrane (CAM) assay for the evaluation of the antitumor and antimetastatic activity of platinum-based drugs in association with the impact on the amino acid metabolism